Browse Category: Medical > Therapeutics

Categories

[Search within category]

A Novel Method to Generate Specific and Permanent Macromolecular Covalent Inhibitors

UCSF researchers have invented a novel method to generate covalent macromolecular inhibitors. This strategy allows a peptide inhibitor to bind to its target protein specifically and irreversibly through proximity-enabled bioreactivity.

Protein Kinase C Epsilon Small Molecule Inhibitors to Treat Pain, Anxiety, Alcoholism, and Nicotine Addiction

This invention provides new inhibitors to protein kinase C epsilon (PKCε) for the treatment and prophylaxis of various diseases such as pain, anxiety, alcoholism, inflammation, cancer, diabetes, and other conditions.

A Mouse Model of Human Papillomavirus (HPV) infection for Drug Discovery

UCSF researchers have generated and validated a K14-HPV16 transgenic mouse model, in which transgene expression produces neoplastic progression that fully resembles the gynecological and other epithelial dysplastic lesions induced by high risk HPVs. This model offers an invaluable tool for studying HPV infection and developing new drugs for HPV treatment.

Deployable Applicators for Ultrasound Therapy

This invention is a modified catheter-based therapeutic ultrasound device with a novel combinatorial assembly of ultrasonic sources, deployable acoustic reflectors, and a fluid lens intended for the delivery of acoustic energy to target tissue. This assembly overcomes restrictions on dimensions required for minimally-invasive surgical introduction into a body cavity or lumen, and when deployed improves depth and range of treatment delivery for hyperthermia, thermal ablation, drug delivery, or sonotherapy.

Repurposing Dabuzalgron to Prevent and Treat Cardiomyopathy and Heart Failure

Using an alpha-1A-adrengic receptor agonist, dabuzalgron, as a therapeutic treatment for cardiomyopathy and heart failure.

Selective Inhibition of Activated ErbB Tyrosine Kinases

This invention identifies a novel class of ErbB targeting small molecules.

A Novel Therapeutic Against HIV Using Human T Cell Immunoglobulin Mucin (TIM-3) Ligands to Modulate Immune Response

Blocking human T cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3) signaling can restore functionality to defective T cells in HIV-1 infected patients. Additionally, measuring TIM-3 provides clinicians with a novel way of evaluating, staging, and monitoring the progression of HIV infections.

HUMAN ANTIBODY TARGETING HIGHLY SPECIFIC TUMOR CELL SURFACE ANTIGEN

These novel antibodies recognize a cell surface antigen that is highly expressed and exclusive to several types of cancers, including mesothelioma, testicular cancer, endometrial cancer, and subsets of ovarian, pancreatic, and non-small cell lung cancers, thereby holding great potential to facilitate the development of novel cancer therapies. 

Deriving Human Naïve Pluripotent Stem Cells by Modifying the Hippo Pathway Using Genetic or Chemical Approaches

This invention identifies a method of generating naïve pluripotent stem cells for subsequent use in research or for regenerative medicine.

Novel Small Molecule CFTR Activators for the Treatment of Constipation

This invention identifies novel small molecule activators of CFTR (cystic fibrosis transmembrane conductance regulator) that can be developed as effective therapies to treat constipation.

Novel Small Molecule CFTR Activators For the Treatment of Dry Eye

This invention identifies novel small molecule activators of CFTR (cystic fibrosis transmembrane conductance regulator) that can be developed as effective therapies for dry eye disorders.

Use of Embryonic Stem Cell-Specific microRNAs to Safely Promote Induced Pluripotency

Novel use of a family of microRNAs to promote the de-differentiation of somatic cells to induce pluripotent stem cells (iPS cells) for use as therapeutic agents or research tools.

A Method to Identify Novel Glucocorticoid Receptor Modulators

This technology establishes a novel method to identify compounds that are either selective or non-selective modulators of glucocorticoid receptor signaling.

Endochondral Tissue Engineering for Vascularized Bone Regeneration

The invention identified a novel translational technique to repair/regenerate damaged bone tissue using a cartilage-derived graft.

Preliminary Small Molecule-mediated Protein Heterodimerization

This technology provides a novel method to effectively modulate protein heterodimerization in a cell by utilizing small molecules.

Novel Compounds Targeting LRH-1for Treatment of Inflammatory Bowel Disease, Type II Diabetes, Triple Negative Breast Cancer & Pancreatic Cancer

This technology contains a method for modulating the activity of the nuclear receptor LRH-1 with identified small molecule compounds that may be developed to treat inflammatory bowel disease, Type II diabetes, triple negative breast cancer and pancreatic cancer.

NOVEL METHOD OF GENERATING HEMATOPOIETIC STEM CELLS

This invention may enable the re-engineering of mature human endothelium (blood vessels) into blood-producing hematopoietic stem cells (HSCs).

Rapid Structure-guided Generation of Antibodies for Detecting Protein Phosphorylation Modifications

This invention is a rapid, robust method to generate high-quality, renewable antibodies specific to protein phosphorylations via antibody scaffolds.

NOVEL GLIOMA-SPECIFIC VACCINE FOR PEDIATRIC AND YOUNG-ADULT PATIENTS

UCSF researchers have developed a vaccine against pediatric gliomas by targeting a novel epitope.  

Methods Of Treating Cancer Using Novel Hsp90/Cdc37 Inhibitors Derived From Cucurbitacin Family

This invention identifies a novel group of cuburbitacin derivatives that inhibit the interaction between Hsp90 and Cdc37, and may be applied to cancer treatment.

TUMOR SELECTIVE MACROPINOCYTOSIS-DEPENDENT RAPIDLY INTERNALIZING ANTIBODIES

This invention establishes a novel method of therapeutic delivery to target tumor cells by macropinocytosis.

An Automated, Minimally-invasive Neural Interface System Providing the Means for Scalable Electrode Implantation

This invention provides an automated, high-throughput, minimally-invasive system to insert electrodes within the brain and other parts of the central nervous system (CNS). The system provides a means for inserting these electrodes within the brain with minimal to no disruption of the blood brain barrier (BBB). This feature is critical, as neural electrode failure is closely associated with inflammation resulting from the disruption of the BBB. Furthermore, this system will allow the implantation of electrodes within the CNS at a much higher density than current standards.

Robust Genome Engineering in Primary Human T Cells using CRISPR/Cas9 Ribonucleoproteins

This invention enables highly effective experimental and therapeutic genomic engineering of primary human T cells and other hematopoietic cells with CRISPR/Cas9 ribonucleoprotein (RNP) technology.  

Novel Predictive Cancer Biomarker for PARP lnhibitors in Cancer Treatment

This novel biomarker predicts the treatment response of PARP inhibitors in cancer patients.

SALT-SPARING UREA TRANSPORT INHIBITOR DIURETICS FOR TREATMENT OF CARDIOVASCULAR AND RENAL DISORDERS

Therapeutic inhibitors of Urea Transporter A (UT-A) as highly effective diuretics with reduced risk of cardiac and neurological side effects for treatment of cardiovascular and renal disorders

  • Go to Page:

ADDRESS

UCSF
Office of Innovation, Technology & Alliances

3333 California Street, Suite S-11,
San Francisco,CA 94143-1209